Table 6. Positivity of antineutrophil cytoplasmic antibodies (ANCA) tests, disease activity score and therapy in AAV patients presenting active disease at study.
| AAV | BVAS score | IIF-ANCA standard technique | IIF-ANCA improved technique | ELISA results | Prednisone daily dose (mg) | Therapy |
|---|---|---|---|---|---|---|
| GPA | 2 | C-ANCA 1/160 | C-ANCA 1/160 | PR3-ANCA | 2.5 | - |
| GPA | 5 | Negative | Negative | PR3-ANCA | 60.0 | Oral cyclophosphamide |
| GPA | 9 | Negative | Negative | PR3-ANCA | 30.0 | Oral cyclophosphamide |
| GPA | 6 | Negative | Negative | PR3-ANCA | 60.0 | iv cyclophosphamide |
| EGPA | 4 | Negative | Negative | Negative | 20.0 | Rituximab |
| EGPA | 3 | Negative | Negative | Negative | 2.5 | Rituximab |
| GPA | 13 | Negative | Negative | Negative | - | - |
| GPA | 8 | Negative | Negative | Negative | 40.0 | - |
AAV: ANCA-associated vasculitis; BVAS: Birmingham Vasculitis Activity Score; EGPA: eosinophilic granulomatosis with polyangiitis; GPA: granulomatosis with polyangiitis; C-ANCA: cytoplasmic ANCA; PR3-ANCA: anti-proteinase 3 ANCA; IIF: indirect immunofluorescence; iv: intravenous.